文献速递心脑血管急症

preHEART评分的外部验证及其与现有临床风险评分在疑似NSTE-ACS院前风险评估中的比较

External validation of the preHEART score and comparison with current clinical risk scores for prehospital risk assessment in patients with suspected NSTE-ACS.
PubMed 文献 · Emerg Med J · 2024-09-25
一句话结论在疑似NSTE-ACS患者中,preHEART评分院前分层低危敏感性92.8%、NPV 92.3%,整体诊断性能与HEART相当且优于T-MACS和单独POC肌钙蛋白。

本研究为荷兰前瞻性多中心队列研究的预设分析,纳入2021年4月至2022年12月经EMS转运至急诊的疑似NSTE-ACS患者,由EMS人员使用preHEART、HEART、T-MACS及POC肌钙蛋白进行风险分层,主要终点为医院NSTE-ACS诊断。823例用于preHEART外部验证,29%(n=235)最终诊断NSTE-ACS;preHEART将27%归为低危,敏感性92.8%(95%CI 88.7-95.7)、NPV 92.3%(95%CI 88.3-95.1),9%归为高危,特异性98.5%(95%CI 97.1-99.3)、PPV 87.7%(95%CI 78.3-93.4)。316例有评分比较数据,preHEART与HEART的AUROC无差异(0.83 vs 0.80,p=0.19),两者均优于T-MACS(p≤0.001和p=0.03)及单独POC肌钙蛋白(p<0.001和p=0.01)。作者认为这些数据支持在院前临床路径中实施临床风险评分。

要点

  • preHEART外部验证:27%归为低危,敏感性92.8%(95%CI 88.7-95.7),NPV 92.3%(95%CI 88.3-95.1)。
  • preHEART高危组占9%,特异性98.5%(95%CI 97.1-99.3),PPV 87.7%(95%CI 78.3-93.4)。
  • preHEART与HEART的AUROC无差异(0.83 vs 0.80,p=0.19)。
  • preHEART优于T-MACS(AUROC 0.72,p≤0.001)和单独POC肌钙蛋白(AUROC 0.71,p<0.001)。
  • HEART优于T-MACS(p=0.03)和单独POC肌钙蛋白(p=0.01)。

适用人群与场景

  • 荷兰2021年4月至2022年12月经EMS转运至急诊的疑似NSTE-ACS患者。
  • 由EMS人员进行风险分层,使用preHEART、HEART、T-MACS和POC肌钙蛋白。

研究设计与关键结果

  • 研究类型:前瞻性多中心队列研究的预设分析;823例用于preHEART外部验证,最终医院诊断NSTE-ACS 29%(n=235)。
  • preHEART低危组占27%,敏感性92.8%(95%CI 88.7-95.7),NPV 92.3%(95%CI 88.3-95.1)。
  • preHEART高危组占9%,特异性98.5%(95%CI 97.1-99.3),PPV 87.7%(95%CI 78.3-93.4)。
  • 316例有评分比较数据:preHEART与HEART的AUROC无差异(0.83(95%CI 0.78-0.87)vs 0.80(95%CI 0.74-0.85),p=0.19)。
  • preHEART优于T-MACS(AUROC 0.72(95%CI 0.66-0.79),p≤0.001)和单独POC肌钙蛋白(AUROC 0.71(95%CI 0.64-0.78),p<0.001)。
  • HEART优于T-MACS(p=0.03)和单独POC肌钙蛋白(p=0.01)。

证据类型、等级与局限

  • 证据类型:前瞻性多中心队列研究的预设分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些数据支持在院前临床路径中实施临床风险评分。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Emergency Medical Services (EMS) studies have shown that prehospital risk stratification and triage decisions in patients with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) can be improved using clinical risk scores with point-of-care (POC) troponin. In current EMS studies, three different clinical risk scores are used in patients suspected of NSTE-ACS: the prehospital History, ECG, Age, Risk and Troponin (preHEART) score, History, ECG, Age, Risk and Troponin (HEART) score and Troponin-only Manchester Acute Coronary Syndromes (T-MACS). The preHEART score lacks external validation and there exists no prospective comparative analysis of the different risk scores within the prehospital setting. The aim of this analysis is to externally validate the preHEART score and compare the diagnostic performance of the these three clinical risk scores and POC-troponin.

METHODS: Prespecified analysis from a prospective, multicentre, cohort study in patients with suspected NSTE-ACS who were transported to an ED between April 2021 and December 2022 in the Netherlands. Risk stratification is performed by EMS personnel using preHEART, HEART, T-MACS and POC-troponin. The primary end point was the hospital diagnosis of NSTE-ACS. The diagnostic performance was expressed as area under the receiver operating characteristic (AUROC), sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV).

RESULTS: A total of 823 patients were included for external validation of the preHEART score, final hospital diagnosis of NSTE-ACS was made in 29% (n=235). The preHEART score classified 27% as low risk, with a sensitivity of 92.8% (95% CI 88.7 to 95.7) and NPV of 92.3% (95% CI 88.3 to 95.1). The preHEART classified 9% of the patients as high risk, with a specificity of 98.5% (95% CI 97.1 to 99.3) and PPV of 87.7% (95% CI 78.3 to 93.4). Data for comparing clinical risk scores and POC-troponin were available in 316 patients. No difference was found between the preHEART score and HEART score (AUROC 0.83 (95% CI 0.78 to 0.87) vs AUROC 0.80 (95% CI 0.74 to 0.85), p=0.19), and both were superior compared with T-MACS (AUROC 0.72 (95% CI 0.66 to 0.79), p≤0.001 and p=0.03, respectively) and POC-troponin measurement alone (AUROC 0.71 (95% CI 0.64 to 0.78), p<0.001 and p=0.01, respectively).

CONCLUSION: On external validation, the preHEART demonstrates good overall diagnostic performance as a prehospital risk stratification tool. Both the preHEART and HEART scores have better overall diagnostic performance compared with T-MACS and sole POC-troponin measurement. These data support the implementation of clinical risk scores in prehospital clinical pathways.

TRIAL REGISTRATION NUMBER: NCT05243485.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Demandt JPA, Koks A, Sagel D, et al. External validation of the preHEART score and comparison with current clinical risk scores for prehospital risk assessment in patients with suspected NSTE-ACS. Emerg Med J. 2024. PMID: 39074964. doi:10.1136/emermed-2023-213866

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。